factor IX

(redirected from BeneFix)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Synonyms for factor IX

coagulation factor whose absence is associated with hemophilia B

References in periodicals archive ?
Benefix Founder and CEO Matt Ranauro said he has seen small-business owners make a number of mistakes when shopping for the right health plan for their companies, including staying with the same plan year to year without looking for a better deal and failing to realize they can offer employees multiple plans.
MidCap Equity Partners, LLC has invested in software provider BeneFix to support continuing growth, the company said.
United States-based Pfizer has revealed positive results from its Phase III trial comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B, it was reported on Friday.
Although the royalty stream from BeneFix has now ended, the Zytiga results are encouraging as this will be a recurring source of revenue for BTG and, should sales continue on the current trajectory, could lead to further earnings upgrades.
"Under the terms of the agreement, Biovitrum will receive a commission on BeneFIX sales, including an additional incentive if certain sales targets are exceeded, for a period of up to five years, with possible one year extensions thereafter," Biovitrum said in a press release.
BTG said "significant growth" in US revenues was generated by BeneFIX, the recombinant Factor IX treatment for Haemophilia B.
M2 EQUITYBITES-July 21, 2014-Pfizer reveals positive results from Phase III trial of BeneFIX
In a separate agreement Sobi and Pfizer have agreed that Sobi will return the co-promotion rights for ReFacto and BeneFIX in the Nordic region to Pfizer from 15 February 2012 in exchange for a payment of USD47.5m.
These are particularly important, given that they help replace BTG's main revenue earning drug BeneFix, which comes off patent around the same time.
Chief executive Mr Ian Harvey said yesterday that he expected to see continued strong growth from BeneFIX, a treatment for haemophilia B.